Key Highlights
- VIR shares fell 13.12% pre-market today to $10.53 from a prior close of $12.12.
- The company priced 15,000,000 shares at $10.00 each.
- Expected gross proceeds are $150 million before discounts and expenses.
- The offering is expected to close on November 16, 2026.
Vir Biotechnology (NASDAQ:VIR) shares slid in pre-market today after the company priced an underwritten public offering of common stock. The stock was at $10.53, down 13.12% from the prior close of $12.12, which followed a 7.69% decline in the previous session.
The offering covers 15,000,000 shares at $10.00 each, about 17.5% below the prior close, for expected gross proceeds of $150 million before Underwriting discounts and expenses. All of the shares are being sold by the company, and the underwriters have a 30-day option to buy up to 2,250,000 additional shares at the offering price, less discounts and commissions.
Vir is a San Francisco-based clinical-stage biopharmaceutical company developing medicines for serious infectious diseases and cancer. Its lead program, the tobevibart and elebsiran combination for chronic hepatitis delta, is in Phase 3.
Offering Follows a Rally on Positive Phase 3 Hepatitis Delta Data
Market data show the shares had rallied sharply earlier in the week on positive Phase 3 ECLIPSE 1 data in hepatitis delta, with an FDA filing planned for mid-2027. The hepatitis delta combination is licensed to Norgine for Europe, Australia and New Zealand.
The shares are being offered under a registration statement filed with the SEC on November 12, which became effective automatically on filing. The pre-market price remains above the $10.00 offering price.
PRO-XTEN T-Cell Engager Platform Anchors the Oncology Pipeline
Vir has a growing oncology portfolio built on its PRO-XTEN dual-masked T-cell engager platform, with candidates including VIR-5500 (PSMA), VIR-5818 (HER2) and VIR-5525 (EGFR), according to market data. The company holds exclusive rights to the PRO-XTEN masking platform for oncology and infectious disease, and it also has preclinical programs across a range of oncologic malignancies.
The 52-week range runs from $5.32 to $14.38. Market data cite price targets of $28 and $30 from two research firms.
Closing Set for November 16 as the Underwriter Option Runs 30 Days
The offering is expected to close on November 16, 2026, subject to customary closing conditions, and the underwriters' option runs for 30 days. Full exercise would add 2,250,000 shares to the 15,000,000 priced. The release did not state how the proceeds will be used, so the closing and any update on the hepatitis delta filing plans are the next points to watch.

_11_17_2026_18_52_19_451299.jpg)




Please wait processing your request...